Effect of Breathing Oxygen-Enriched Air on Exercise Performance in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Crossover Trial

Müller, Julian; Lichtblau, Mona; Saxer, Stéphanie; Calendo, Luigi-Riccardo; Carta, Arcangelo F; Schneider, Simon R; Berlier, Charlotte; Furian, Michael; Bloch, Konrad E; Schwarz, Esther Irene; Ulrich, Silvia

Abstract: Objective: To evaluate the effects of breathing oxygen-enriched air (oxygen) on exercise performance in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). Methods: Ten patients with PH-HFpEF (five women, age 60 ± 9 y, mPAP 37 ± 14 mmHg, PAWP 18 ± 2 mmHg, PVR 3 ± 3 WU, resting SpO2 98 ± 2%) performed two-cycle incremental exercise tests (IET) and two constant-work-rate exercise test (CWRET) at 75% maximal work-rate (W max), each with ambient air (FiO2 0.21) and oxygen (FiO2 0.5) in a randomized, single-blinded, cross-over design. The main outcomes were the change in W max (IET) and cycling time (CWRET) with oxygen vs. air. Blood gases at rest and end-exercise, dyspnea by Borg CR10 score at end-exercise; continuous SpO2, minute ventilation (V'E), carbon dioxide output (V'CO2), and cerebral and quadricep muscle tissue oxygenation (CTO and QMTO) were measured. Results: With oxygen vs. air, W max (IET) increased from 94 ± 36 to 99 ± 36 W, mean difference (95% CI) 5.4 (0.9-9.8) W, p = 0.025, and cycling time (CWRET) from 532 ± 203 to 680 ± 76 s, +148 (31.8-264) s, p = 0.018. At end-exercise with oxygen, Borg dyspnea score and V'E/V'CO2 were lower, whereas PaO2 and end-tidal PaCO2 were higher. Other parameters were unchanged. Conclusion: Patients with PH-HFpEF not revealing resting hypoxemia significantly improved their exercise performance while breathing oxygen-enriched air along with less subjective dyspnea sensation, a better blood oxygenation, and an enhanced ventilatory efficiency. Future studies should investigate whether prolonged training with supplemental oxygen would increase the training effect and, potentially, daily activity for PH-HFpEF patients. Clinical Trial Registration: [clinicaltrials.gov], identifier [NCT04157660]. Keywords: cardiopulmonary exercise test; exercise; external cycling work; heart failure with preserved ejection fraction; oxygen therapy; pulmonary hypertension

DOI: https://doi.org/10.3389/fmed.2021.692029

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-211866
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.
Effect of Breathing Oxygen-Enriched Air on Exercise Performance in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Crossover Trial

Julian Müller 1,2†, Mona Lichtblau 1,2†, Stéphanie Saxer 1,2†, Luigi-Riccardo Calendo 1,2, Arcangelo F. Carta 1,2, Simon R. Schneider 1,2, Charlotte Berlier 1,2, Michael Furian 1,2, Konrad E. Bloch 1,2,3, Esther I. Schwarz 1,2 and Silvia Ulrich 1,2,3*

1 Pulmonary Clinic, University Hospital Zürich, Zürich, Switzerland, 2 Faculty of Medicine, University of Zürich, Zürich, Switzerland, 3 Centre for Integrative Human Physiology, University of Zürich, Zürich, Switzerland

Objective: To evaluate the effects of breathing oxygen-enriched air (oxygen) on exercise performance in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

Methods: Ten patients with PH-HFpEF (five women, age 60 ± 9 y, mPAP 37 ± 14 mmHg, PAWP 18 ± 2 mmHg, PVR 3 ± 3 WU, resting SpO2 98 ± 2%) performed two-cycle incremental exercise tests (IET) and two constant-work-rate exercise tests (CWRET) at 75% maximal work-rate (Wmax), each with ambient air (FiO2 0.21) and oxygen (FiO2 0.5) in a randomized, single-blinded, cross-over design. The main outcomes were the change in Wmax (IET) and cycling time (CWRET) with oxygen vs. air. Blood gases at rest and end-exercise, dyspnea by Borg CR10 score at end-exercise; continuous SpO2, minute ventilation (V'E), carbon dioxide output (V'CO2), and cerebral and quadriceps muscle tissue oxygenation (CTO and QMTO) were measured.

Results: With oxygen vs. air, Wmax (IET) increased from 94 ± 36 to 99 ± 36 W, mean difference (95% CI) 5.4 (0.9–9.8) W, p = 0.025, and cycling time (CWRET) from 532 ± 203 to 680 ± 76 s, +148 (31.8–264) s, p = 0.018. At end-exercise with oxygen, Borg dyspnea score and V'E/V'CO2 were lower, whereas PaO2 and end-tidal PaCO2 were higher. Other parameters were unchanged.

Conclusion: Patients with PH-HFpEF not revealing resting hypoxemia significantly improved their exercise performance while breathing oxygen-enriched air along with less subjective dyspnea sensation, a better blood oxygenation, and an enhanced ventilatory efficiency. Future studies should investigate whether prolonged training with supplemental oxygen would increase the training effect and, potentially, daily activity for PH-HFpEF patients.
INTRODUCTION

In patients with heart failure with preserved ejection fraction (HFpEF), pulmonary hypertension (PH) is frequent and associated with reduced quality of life, exercise intolerance, disease progression, morbidity, and mortality (1, 2). Reduced exercise capacity in HFpEF has been associated with adverse outcomes such as reduction in quality of life and increased mortality. Despite multiple international efforts, no pharmacological treatment has been identified that can effectively reduce mortality in HFpEF. However, with medical therapy a substantial improvement in exercise capacity without change in cardiac function has been reported in a meta-analysis by Holland et al. (3). Exercise training has been strongly associated with an increase in exercise capacity and quality of life in this patient collective, which is difficult to treat (4). Exercise intolerance in patients with heart failure has been attributed to multiple factors, including impaired cardiopulmonary reserve, a reduction of peripheral and respiratory skeletal muscle function, and mitochondrial dysfunction (1, 5, 6).

In healthy subjects, patients with pulmonary arterial (PAH) or chronic thromboembolic PH (CTEPH), or patients with chronic obstructive pulmonary disease (COPD), breathing oxygen-enriched air during cycling exercise is associated with an increased maximal work-rate (Wmax) and constant work-rate exercise test (CWRET) time compared to breathing ambient air (7–9). Several mechanisms of the oxygen pathway are improved with higher arterial oxygenation in those patients, namely, increased oxygen availability to the muscle and cerebral tissue and also improved ventilatory efficiency.

While long-term oxygen therapy is recommended for hypoxemic patients with PH-HFpEF (10), so far, no study has assessed the potential role of oxygen during exercise training in non-hypoxemic PH-HFpEF.

The purpose of the current randomized, sham-controlled trial is therefore to test the hypotheses that oxygen-enriched air (oxygen, FiO2 0.50) increases exercise capacity in an incremental (ramp) exercise test (IET) and cycling time in a high-intensity CWRET in stable PH-HFpEF patients without resting hypoxemia, compared to ambient air (air, FiO2 0.21).

MATERIALS AND METHODS

Study Design

This randomized, placebo-controlled, single-blinded, cross-over trial evaluated the effect of oxygen therapy in improving exercise performance in non-hypoxemic patients with PH-HFpEF using IET and CWRET protocols twice, once with and once without oxygen supplementation in randomized order, as described previously (8, 9). The study was conducted in accordance with the amended declaration of Helsinki (11), approved by the institutional ethical committee (KEK 2012-0251), and registered at ClinicalTrials.gov (NCT04157660), and participants gave their written informed consent.

Participants

Patients with PH-HFpEF diagnosed by right heart catheterization [pulmonary artery wedge pressure (PAWP) > 15 mmHg, mean pulmonary artery pressure (mPAP) > 25 mmHg] and normal left ventricular ejection fraction (LVEF > 50%), aged 18–80 years, were included (12). The participants were stable on the same medication for the last 4 weeks and had no relevant co-morbidities, no chronic lung disease, no musculoskeletal limitation, and were not pregnant. Any other unstable condition or contraindication for ergo-spirometry led to exclusion.

Interventions

On two separate days, patients performed each two-cycle exercise tests at rates of 50–60 rpm to exhaustion: On the first day, patients underwent two IETs with increments of 10–20 W/min according to the patient’s fitness; on the second day, two CWRETs at 75% of individual Wmax achieved with air. In both tests (IET and CWRET), the work-rate started after 120 s of cycling without resistance. There was a recovery period for at least 2 h between the tests. For each test, patients were breathing either air or oxygen in a randomized order. Subjects were connected to the flow sensor of a metabolic unit via a mouthpiece (Ergostick, Geratherm Medical, Geschwenda, Germany) and a low-resistance two-way valve (Hans Rudolph, Shawnee, USA). The inlet of the valve was connected to a gas-mixing device to provide either air or oxygen (Altitrainer, SNTEC SA, Nyon, Switzerland). The metabolic unit was calibrated before each test. The patients were blinded to the oxygen settings.

Assessments

Clinical and diagnostic assessments were performed as described previously (9, 13): At the screening visit, medical history, clinical examination, 6-min walk test (6MWT), and spirometry were noted. Prior to the test at interventional days, patients were not allowed to do sports and drink alcohol, coffee, or carbonated drinks and were instructed to take their regular medication and to eat a light meal more than an hour before.

Respiratory gas exchange was recorded with the metabolic unit. Breathing rate, tidal volume (Vt), minute ventilation (V’E), CO2 output (V’CO2), and derived variables were recorded breath by breath. Oxygen uptake is not reported for tests with oxygen because accuracy of the O2-sensor outside the calibration range of FiO2 0.16–0.21 could not be verified. Heart rate was derived from a 12-lead ECG and blood pressure was measured by automated arm-cuff measurements. Finger pulse oximetry (SpO2) and cerebral and quadricep muscle tissue oxygenation...
(CTO, QMTO) were recorded by near-infrared-spectroscopy sensors (NIRO-200NX, Hamamatsu, Shizuoka, Japan) (14–16).

Physiological variables were recorded breath by breath and averaged over successive 30 s intervals. Variables at end-exercise were defined as a mean over the final 30 s before the termination of the exercise defined as a drop in cycling rate < 50 rpm. The ventilatory equivalents for $V’CO_2$ were calculated as $V’E/V’CO_2$ at end-exercise and $V’E/V’CO_2$ as slope over the entire duration of ramp exercise (17). Isotime was defined as the final 30 s to end-exercise of the shorter test compared with the longer test at the same time point. Reference values for $W_{max}$ were those reported by Glaser et al. (18).

**Main Outcome**
Co-primary outcomes were the change in maximal work-rate during IET (part 1) and the change in cycling time during high-intensity CWRET (part 2).

**Randomization and Blinding**
The two different conditions (air vs. oxygen) were randomized by software-based block randomization for the first test day. At the second test day the same order was maintained. Participants were blinded to the $FiO_2$.
Sample Size and Statistics
Based on previous studies on oxygen therapy in patients with pulmonary hypertension (8) and chronic obstructive pulmonary disease (9), a sample size estimation indicated that 10 participants were required to detect a difference of 5 W in IET and 2 min in CWRET (19, 20) with a power of 0.8 and alpha level of 0.05 for both trials. Normal distribution of data differences was assessed with the Kolmogorov–Smirnov test. Data are summarized as mean ± standard deviation (SD), mean difference, and 95% confidence interval (CI) between air and oxygen. As all participants had complete data sets, the results correspond to both an intention-to-treat and per-protocol analysis. Data from the tests (IET or CWRET) with air and oxygen were compared at end-exercise and at identical times corresponding to end-exercise with the shorter tests (isotime). Data from IET with air and oxygen were further compared over the progressive course of exercise at corresponding exercise times, respectively, work-rate at submaximal exercise intensity. We therefore computed the means over each 10% fraction of maximal exercise duration individually achieved with air, i.e., 1–10%, 11–20%, etc., up to 91–100% of the total exercise duration, and comparatively computed the corresponding means over identical time periods in tests with oxygen, as described before (9, 13). Linear mixed regression analyses were used to explore changes in $W_{\text{max}}$ (IET) or cycling time (CWRET) induced by oxygen and adjusted for baseline variables [body mass index (BMI), age, sex, New York Heart Association Functional Classification (NYHA-Class), LVEF, 6-Min Walk Test (6MWT)]. To investigate the differences in delivered external work (J) with oxygen vs. air, the two tests (CWRET and IET) were compared by calculating the integral of power (W) over time (s). Significance was assumed at $p < 0.05$, with 95% CI not overlapping zero. Data were analyzed with the statistical programs SPSS Version 26 (SPSS, Chicago, IL, USA) and R studio version 1.2.1578, and the graphs were drawn with Matlab version R2017b.

RESULTS
Figure 1 shows the patient flow, and baseline characteristics are presented in Table 1. Of seventy-four patients having been assessed for PH-HFpEF by right heart catheter, we were able to randomize 10 patients (two combined pre- and post-capillary, eight post-capillary PH) and these patients completed all tests according to the protocol between September 2019 and January 2020. The patients were on average 60 ± 9 years old with a BMI of 28 ± 6 kg/m². Five of 10 were female, and all were on stable medical treatment for heart failure according to guidelines and revealed comorbidities, as expected. Mean LVEF was 63 ± 5%, SpO₂ at rest 98 ± 2% and 6-min walking distance 495 ± 54 m (Table 1).

Incremental (Ramp) Cycle Exercise
Table 2 and Figures 2 and 3 summarize the results of the IET. With air, $W_{\text{max}}$ was reduced compared to predicted normal values (94 ± 36 W, 61 ± 14% predicted). Oxygen significantly increased $W_{\text{max}}$ to 99 ± 36.3 W, corresponding to a mean change (95% confidence interval) of +5.4 W (0.9–9.8, $p = 0.025$). At end-exercise, patient-reported Borg CR10 dyspnea score was significantly reduced with oxygen from 6.9 ± 1.7 to 6.1 ± 1.3, corresponding to a mean change of −0.8 (−1.5 to −0.1, $p = 0.039$). Borg CR10 scores for leg discomfort did not differ from values under air.

Oxygen increased SpO₂, CTO, and QMTO by 5, 7 and 2% at end-exercise compared with air (Figure 3). Arterial blood gas analysis at maximal exercise revealed an increase in $SaO₂$ and $PaO₂$ under oxygen vs. air, while arterial pH remained unchanged even though the arterial lactate was slightly but not significantly higher under oxygen compared to air. Heart rate was reduced at end-exercise under oxygen. Breathing reserve was reduced by −4% with oxygen, while breathing rate was unchanged.

### Table 1 | Baseline characteristics.

| Characteristic                              | N (%), Mean ± SD |
|---------------------------------------------|------------------|
| Number of participants                      | 10               |
| Female; male                               | 5; 5             |
| Age (years)                                 | 60 ± 9           |
| Body mass index (kg/m²)                    | 28 ± 6           |
| New York Heart Association functional class I/II | 7 (70%)         |
| New York Heart Association functional class III | 3 (30%)         |
| Left ventricular ejection fraction (%)      | 63 ± 5           |
| Medication:                                 |                  |
| Diuretics                                  | 10 (100)         |
| beta-Blocker                               | 3 (30)           |
| ACE inhibitors                             | 3 (30)           |
| AT-2 blocker                               | 1 (10)           |
| Calcium antagonists                        | 6 (60)           |
| Right heart catheterization data:          |                  |
| Heart rate (bpm)                            | 74 ± 10          |
| Systolic blood pressure (mmHg)              | 140 ± 25         |
| Diastolic blood pressure (mmHg)             | 77 ± 8           |
| Mean pulmonary artery pressure (mmHg)       | 37 ± 14          |
| Pulmonary artery wedge pressure (mmHg)      | 18 ± 2           |
| Cardiac index (L/min/m²)                    | 3.4 ± 0.8        |
| Pulmonary vascular resistance, (WU)         | 3 ± 3            |
| Pulmonary vascular resistance >3WU          | 2                |
| SpO₂ rest (%)                              | 98 ± 2           |
| 6-min walking distance (m)                  | 496 ± 54         |
| SpO₂ at end of 6-min walk (%)               | 95 ± 5           |
| Co-morbidities:                             |                  |
| Obesity                                     | 2 (20)           |
| Arterial hypertension                       | 3 (30)           |
| Coronary heart disease                      | 1 (10)           |
| Diabetes                                    | 2 (20)           |
| Cardiomyopathy                              | 1 (10)           |
| Pulmonary emphysema                         | 1 (10)           |
| Atrial fibrillation                         | 1 (10)           |
| Systematic sclerosis                        | 1 (10)           |
| Hypercholesterolemia                        | 3 (30)           |

Values are presented as mean ± SD or total number (%). ACE, angiotensin converting enzyme; AT-2, angiotensin-2 receptor; SpO₂, arterial oxygen saturation.
TABLE 2 | Results of the incremental exercise test.

| IET                      | Air         | End-exercise | Oxygen     | Isotime |
|--------------------------|-------------|--------------|------------|---------|
|                          | Mean        | Difference (95% CI) | Mean        | Difference (95% CI) |
| Maximal work-rate (W)    | 93.6 ± 36.2 | 99 ± 36.3* 5.4 (0.9/9.8); +6% (1/11) | 93 ± 36 | NA |
| Exercise time (s)        | 481 ± 128   | 540 ± 133** 60 (33/86) | 478 ± 122 | NA |
| Heart rate (bpm)         | 117 ± 30    | 108 ± 39 −9 (−38/22) | 108 ± 44 | −18.1 (−52/16) |
| Heart rate reserve (bpm)| 41 ± 32     | 45 ± 40 4 (−25/34) | 37.4 ± 28.1 | 3 (−2/8) |
| V'E (L/min)              | 39.6 ± 22   | 44 ± 12 4.7 (−8/17) | 43 ± 13 | 2 (−12/16) |
| Breathing reserve (%MVV) | 61 ± 28     | 57 ± 25 −4 (−15/7.6/8) | 57.8 ± 25.1 | −2 (−14.3/10.3) |
| Tidal volume (L)         | 1.1 ± 0.6   | 1.2 ± 0.6 0.1 (−0.3/0.4) | 1.16 ± 0.65 | 0.09 (−0.3/0.5) |
| Breathing rate (1/min)   | 30.4 ± 5.2  | 30.4 ± 6 0 (−2/6.4) | 29.4 ± 6.3 | −2.7 (−6.5/1.1) |
| V'CO₂ (L/min)            | 0.8 ± 0.6   | 1.0 ± 0.6 0.2 (−0.1/0.4) | 0.93 ± 0.57 | 0.09 (−0.2/0.4) |
| V'E/V'CO₂                | 34.8 ± 3    | 31.7 ± 2.6** −3.1 (−4.4/−1.8) | 31.4 ± 2.8** −3.8 (−5.4/−2.1) | NA |
| V'E/V'CO₂ slope          | 32.2 ± 5.1  | 29 ± 3.8* −3.3 (−5.9/−0.6) | NA | NA |
| End-tidal PaCO₂ (mmHg)   | 31.5 ± 5.4  | 34.7 ± 6.8** 3.2 (1.5/5.3) | 35.1 ± 7.0** 4 (1.9/6.1) | NA |
| Systolic blood pressure (mmHg) | 157 ± 27 | 163 ± 20 6 (−8/21) | 157 ± 22 | −3 (−12/8) |
| Diastolic blood pressure (mmHg) | 81 ± 26 | 87 ± 30 6 (−13/26) | 90 ± 29 | 1.4 (−8/11) |
| SpO₂ (%)                 | 92 ± 2      | 97 ± 2** 5 (3/7) | 97 ± 2** 5 (3/6) | NA |
| CTO (%)                  | 59 ± 21     | 66 ± 11 7 (−6/20) | 62 ± 23 | 3 (−4/10) |
| QMTO (%)                 | 54 ± 20     | 56 ± 22 2 (−2/6) | 56 ± 22 | 2 (−3/7) |
| Arterial pH              | 7.39 ± 0.05 | 7.39 ± 0.05 0 (−0.03/0.02) | NA | NA |
| PaO₂ (kPa)               | 11.7 ± 3.3  | 26.5 ± 10** 14.8 (5.9/23.6) | NA | NA |
| PaCO₂ (kPa)              | 4.6 ± 0.5   | 4.8 ± 0.7 0.2 (−0.1/0.5) | NA | NA |
| SaO₂ (%)                 | 96 ± 3.6    | 99 ± 0.7* 3 (0.6/5.9) | NA | NA |
| Arterial lactate (mmol/L) | 4.4 ± 2.7   | 4.6 ± 1.8 0.2 (−1.6/2.0) | NA | NA |
| Arterial HCO₃ (mmol/L)    | 21.9 ± 2    | 22.3 ± 2.2 0.4 (−0.6/1.5) | NA | NA |
| Borg CR10 dysp. score    | 6.9 ± 1.7   | 6.1 ± 1.3 −0.8 (−1.5/−0.1) | NA | NA |
| Borg CR10 leg score      | 7.3 ± 1.3   | 7.4 ± 1.5 0.1 (−0.5/0.7) | NA | NA |

Values are presented as mean ± SD, n = 10. End-exercise represents the values averaged over the last 30 s. Isotime refers to the identical time of end-exercise of the shorter test. MVV, maximal voluntary ventilation; SpO₂, pulse oximetry; CTO, cerebral tissue oxygenation; QMTO, quadriceps muscle tissue oxygenation; PaO₂, arterial partial pressure of oxygen; PaCO₂, arterial partial pressure of carbon dioxide; SaO₂, arterial oxygen saturation; NA, not available. *p < 0.05; **p < 0.01.

FIGURE 2 | Improvements of the primary outcomes with oxygen. Changes of maximal work-rate (W_max (W)) at the incremental exercise test (left, purple) and mean changes of maximal cycling time [t (s)] of the constant work-rate exercise test (right, green) with oxygen-enriched vs. ambient air are shown as mean ± standard error of mean (SEM). IET, incremental exercise test; CWRET, constant work-rate exercise test.

At end-exercise as well as at isotime, V'CO₂ and V'E were unchanged with oxygen, while V'E/V'CO₂ at end-exercise and the V'E/V'CO₂ slope were significantly reduced, indicating increased ventilatory efficiency while breathing oxygen. W_max was higher and end-tidal PaCO₂ increased significantly under oxygen to 34.7 ± 6.8 mmHg, corresponding to a mean change of +3.2 mmHg (1.1–5.3, p = 0.007).

Linear mixed regression analyses revealed no correlations between baseline characteristics and the improvement of W_max with oxygen.

Constant Work-Rate Cycle Exercise

The results of the CWRET at end-exercise and isotime under oxygen vs. air are summarized in Table 3. CWRET with 75% of W_max determined under air corresponded to a mean work-rate of 70 ± 27 W. Breathing oxygen improved cycling time from a mean value of 532 ± 203 s under air to 680 ± 276 s, corresponding to a mean change of 148 s (32–264, p = 0.018) (Figure 2). Under oxygen, 5/10 patients increased their exercise time by >10% and 3/10 by >40%. Two patients decreased cycling time with oxygen by 122 and 55 s, respectively.

At end-exercise breathing reserve increased by 6% under oxygen, while breathing rate was reduced. The patients perceived
significantly less dyspnea under oxygen, decreasing Borg CR10 dyspnea scores from 7.4 ± 1.6 to 6.1 ± 2.0, corresponding to a mean change of −1.3 (−2.6 to −0.1, p = 0.045). SpO2 and CTO both increased by 4.0 and 7.9% under oxygen, whereas QMTO was unchanged. Arterial blood gas analysis resulted in higher PaO2, SaO2, and PaCO2 with oxygen than air but lower lactate concentrations.

At isotime, heart rate under oxygen was significantly reduced corresponding to a mean change of −5 bpm (−8 to −1, p = 0.031), breathing reserve was increased by 9%, while breathing rate and VE were significantly reduced. CTO, SpO2, and QMTO increased to 3, 4, and 7% with oxygen.

Linear mixed regression analyses revealed no correlations between baseline characteristics and improvement of cycling time with oxygen.

External Cycling Work Delivery
In CWRET under air, participants cycled for a mean time of 418 s (under resistance, 538–120 s) with a mean work-rate of 70 W. In IET under air, participants cycled for a mean time of 361 s (under resistance, 481–120 s) with a mean work-rate of 94 W (Figures 4A, B). By integral calculation of work-rate over cycling time, the delivered mean external work with air results in 30,982 J during the CWRET and 22,068 J during the IET (Figure 4C). Under oxygen, patients cycled for a mean time of 560 s (680–120 s) with a mean work-rate of 70 W and delivered an external work of 42,016 J during CWRET and, for 420 s (540–120 s) with 99 W, they delivered 26,475 J of external work during IET (Figure 4D).

Accordingly, patients delivered significantly more external cycling work during the CWRET compared to the IET (+40% with air, mean change 8,914 J (1,522 to 16,306), p = 0.023; +59% with oxygen, mean change 15,541 J (2,953 to 28,129), p = 0.021).

Breathing oxygen was associated with a higher production of external work (CWRET: +36% and IET: +20%, p = 0.051 and 0.002).

DISCUSSION
This randomized, placebo-controlled, single-blinded, cross-over study in patients with PH-HFpEF without resting hypoxemia shows for the first time that breathing oxygen significantly enhances cycling exercise performance in terms of Wmax in IET and cycling time in CWRET along with less dyspnea perception and a higher ventilatory efficacy.

The highest improvement of exercise performance was a 28% increase in CWRET cycling time (2.5 min) with oxygen compared to air, which is well above a postulated clinical important difference of 1.75 min for patients with COPD (19). This surpasses the relatively small improvement of 6% increase in Wmax in the IET with oxygen. We assume that this is due to the fact that participants could exercise longer with the aerobic energy generating pathway in the CWRET, below the limit of the anaerobic threshold, which was in turn substantially raised by breathing oxygen.

The improvements in exercise performance with oxygen vs. air were associated with a higher blood oxygenation (SpO2, SaO2, PaO2) over the entire course of exercise (Figure 3). Similarly, albeit not significant, CTO and QMTO were improved, pointing toward a higher tissue oxygenation related to the higher arterial oxygen content and possibly an increased VO2 with oxygen. By increasing FIO2 (normobaric hyperoxia) larger amounts of O2 will physically be dissolved in the arterial blood plasma and also bound to the hemoglobin to improve the SaO2 and increase the arterial oxygen content (21). It is supposed that breathing oxygen-enriched air (FiO2 > 0.21) triggers different cellular, molecular, neuronal, hormonal, and enzymatic responses that are leading to an ergogenic effect in maximal as well as submaximal loads (21–25). There is evidence that the intracellular pO2 could lead to more diffusion of O2 from the capillaries to the muscle cells (25); also there could be more effective oxygen storages with reduced dependencies to substrate phosphorylation.
TABLE 3 | Results of the constant work-rate exercise test.

| CWRET | Air | End-exercise | Oxygen | Isotime |
|-------|-----|--------------|--------|--------|
| Mean  | Mean | Difference (95% CI) | Mean  | Difference (95% CI) |
| Mean  | Mean | Difference (95% CI)  |
| Cycling time (s) | 532 ± 203 | 680 ± 276* | 148 (32/264) +28% (6/50) | 520 ± 200 | NA |
| Work-rate (W) | 70 ± 27 | 70 ± 27 | NA | 70 ± 27 | NA |
| Heart rate (bpm) | 121 ± 30 | 120 ± 29 | −1 (−5/4) | 117 ± 29* | −4.5 (−9/−1) |
| Heart rate reserve (bpm) | 47 ± 49 | 34 ± 31 | −13 (−42/16) | 37 ± 32 | −8.9 (−38/20) |
| V'CO (L/min) | 47 ± 12 | 37 ± 13 | −9.6 (−20/1) | 39 ± 8** | −9 (−10/−7) |
| Breathing reserve (%MVV) | 62.7 ± 21.3 | 68.6 ± 16.3 | 5.9 (−2.5/14.3) | 70 ± 15.6 | 9 (0.6/20) |
| Tidal volume (L) | 1.3 ± 0.7 | 1.2 ± 0.6 | −0.1 (−0.4/0.1) | 1.2 ± 0.6 | −0.1 (−0.4/0.2) |
| Breathing rate (L/min) | 31.5 ± 7.0 | 29.1 ± 5.4 | −2.4 (5.3/0.5) | 25.5 ± 3.9* | −5.9 (−10.7/−1.1) |
| V'CO2 (L/min) | 0.9 ± 0.5 | 0.9 ± 0.5 | −0.06 (−0.3/0.1) | 0.9 ± 0.5 | −0.1 (−0.4/0.2) |
| V'VE/V'CO2 | 36.6 ± 4.6 | 32.2 ± 3.8** | −4.3 (−7.3/−1.5) | 31.5 ± 2.9** | −5.8 (−8.3/−3.2) |
| End-tidal PaCO2 (mmHg) | 31.1 ± 4.0 | 34.2 ± 4.4** | 3.1 (1.1/5.1) | 35.4 ± 4.3** | 4.3 (2.6/6.1) |
| Systolic blood pressure (mmHg) | 180 ± 34 | 160 ± 36 | −20 (−43/4) | 166 ± 38 | −1 (−34/31) |
| Diastolic blood pressure (mmHg) | 87 ± 14 | 81 ± 20 | −6 (−30/18) | 78 ± 22 | 7 (−33/19) |
| SpO2 (%) | 91 ± 7 | 95 ± 4 | 4 (−1/9) | 95 ± 4 | 4 (−1/8) |
| CTO (%) | 57 ± 20 | 65 ± 12 | 8 (−10/26) | 98 ± 3* | 3 (1/6) |
| QMTO (%) | 57 ± 21 | 58 ± 21 | 1 (−5/5) | 64 ± 10 | 7 (−9/24) |
| Arterial pH | 7.39 ± 0.06 | 7.38 ± 0.06* | −0.01 (−0.03/−0.0) | NA | NA |
| PaO2 (kPa) | 9.4 ± 1.7 | 32.8 ± 4.6** | 23.4 (19.2/27.8) | NA | NA |
| PaCO2 (kPa) | 4.6 ± 0.4 | 4.8 ± 0.3 | 0.25 (−0.1/0.6) | NA | NA |
| SaO2 (%) | 93.7 ± 4.1 | 99.8 ± 0.2** | 6.1 (−9.9/−2.25) | NA | NA |
| Arterial lactate (mmol/L) | 5.9 ± 2.9 | 5.2 ± 2.7 | −0.7 (−1.9/0.6) | NA | NA |
| Arterial HCO3 (mmol/L) | 21.9 ± 2.9 | 21.9 ± 3.0 | 0.04 (−1.2/1.1) | NA | NA |
| Borg CR10 dysp. score | 7.4 ± 1.6 | 6.1 ± 2.0 | −1.3 (−2.6/−0.04) | NA | NA |
| Borg CR10 leg score | 6.8 ± 1.7 | 6 ± 1.6 | 0.8 (−0.8/2) | NA | NA |

Values are presented as mean ± SD, n = 10. End-exercise represents the values averaged over the last 30 s. Isotime refers to the identical time of end-exercise of the shorter test. MVV, maximal voluntary ventilation; SpO2, pulse oximetry; CTO, cerebral tissue oxygenation; QMTO, quadriceps muscle tissue oxygenation; PaO2, arterial partial pressure of oxygen; PaCO2, arterial partial pressure of carbon dioxide; SaO2, arterial oxygen saturation; NA, not available. *p < 0.05; **p > 0.01.

with reduced anaerobic metabolism and different recruitment patterns of muscle fibers (26) to enhance exercise performance. In addition, the influence of the central nervous system by reducing fatigue as a "central governor" (22) or regulating hormonal release especially reduced levels of catecholamines (27, 28). Additionally, enzymatic protecting reactions like extracellular superoxide dismutase activity to reduce oxidative stress and damage (23) could all contribute essentially to the ergogenic effect of breathing oxygen-enriched air.

Therefore, exercise performance under oxygen may have been enhanced by improved tissue oxygenation by promoting the availability of oxygen in working muscles and in the cerebral motor and sensory neurons while reducing dyspnea perception despite the higher intensity and longer duration of exercise. In the literature, there is a growing body of evidence that suggests that non-cardiac factors like morphological changes in the periphery, such as skeletal muscles, may play an important role in exercise intolerance in HFpEF-patients. It is suspected that changes in mitochondrial structures, a decrease of capillary density, and a conversion of type 1 muscle fibers to type 2 muscle fibers may be the primary factors for impaired oxygen uptake and utilization (29, 30). The QMTO values measured in this study, which only increased marginally with oxygen, compared with other patient groups previously investigated, could support this theory (7–9).

Under oxygen, the maximum heart rate was reduced, an important finding in PH due to HFpEF patients, as a reduced heart rate signifies less autonomic stress, allows for increased cardiac filling, and is associated with a better prognosis and survival in heart failure (31). With the heart rate lowering effect of oxygen during physical exercise, patients reach their upper heart rate limit later and can therefore achieve higher exercise performance while breathing oxygen-enriched air.

Breathing oxygen was associated with a reduction of V'E/V'CO2 at end-exercise and the V'E/V'CO2 slope, while breathing rates and ventilation remained unchanged or reduced despite a longer exercise duration and/or higher work-rates, thus indicating an improved ventilatory efficiency. Furthermore, it has been shown that in patients with chronic heart failure, lower breathing rates increase arterial baroreflex sensitivity and improve exercise capacity (32).
the content of oxygen in the blood plays a subordinate role and the exercise performance depends mainly on the anaerobic capacity, as well as on the muscular leg strength. In all tests at end-exercise, lactate values were >4 mmol/L indicating a high acidic load just before cessation. However, arterial pH and bicarbonate concentration and breathing rate were unchanged, possibly indicating that maximal muscular exhaustion was reached before the maximal cardiorespiratory limitation.

Our previous trials in patients with precapillary PH and COPD demonstrated even larger exercise enhancing effects with oxygen compared to the presently investigated PH-HFpEF patients (8, 9), which might indicate that the beneficial effect of oxygen may be enhanced when exercise-induced
or resting hypoxemia is present, like in patients with lung disease or PAH and CTEPH. However, other studies in healthy volunteers and athletes revealed that breathing oxygen-enriched air during exercise may be associated with an increase of up to 30% in maximal power output and up to 130% endurance time compared with ambient air, which indicates that the beneficial effects of oxygen therapy on exercise performance are consistently found in many different populations albeit to a varying magnitude (25, 33–37).

**Effect of Oxygen on Delivered External Cycling Work**

Patients delivered significantly larger amounts of external work in the CWRET compared with the IET under both conditions (oxygen and air) despite the higher work-rate reached in shorter time in the IET. This may indicate that the patients did not stop the IET because of the exhausted energy resources but because of a lack of anaerobic capacity and leg muscle strength. For both tests (IET and CWRET), an increase of total delivered external work while breathing oxygen compared to air was found, even though the increase in maximal cycling time in CWRET was 28% with oxygen, whereas $W_{\text{max}}$ in IET only increased by 6%. Despite higher relative increase in cycling time in CWRET compared to the $W_{\text{max}}$ in IET, the increase in external work delivery was 36% in CWRET and 20% in IET with oxygen vs. air, indicating an improvement not only of endurance but also of the capacity of expending external cycling work and possibly enhanced work efficiency with oxygen breathing during exercise.

**CONCLUSION**

This randomized, placebo-controlled trial showed for the first time a significantly improved exercise performance by breathing oxygen in patients with PH due to HFP EF in both IET and CWRET protocols, along with less dyspnea perception, better blood oxygenation, a lower maximal heart rate, and improved ventilatory efficiency. Comparison of IET and CWRET in terms of produced energy suggests that PH-HFpEF patients benefit from oxygen in both protocols but are able to produce higher energy levels on an aerobic energy-generating pathway. These improvements of exercise performance are of potential relevance to improve the training intensity and, potentially, the daily activity of PH-HFpEF patients.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Kantonale Ethikkommission Zürich. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

SU, ML, SS, ES, and KB contributed to the conception and design. JM, ML, SS, L-RC, AC, KB, ES, and SU contributed to the acquisition, analysis, or interpretation of data. JM, ML, SS, and SU drafted the manuscript. All authors revised the manuscript critically for important intellectual content.

**FUNDING**

This work was supported by grants of the Swiss National Science Foundation, Physiowiss, and the Zurich Lung League.

**REFERENCES**

1. Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, et al. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol. (2019) 73:2209-25. doi: 10.1016/j.jacc.2019.01.072
2. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. (2016) 37:942-54. doi: 10.1093/eurheartj/ehv512
3. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment (oxygen and air) despite the higher work-rate reached in shorter time.
4. Taylor RS, Walker S, Smart NA, Pietpoli MF, Warren FC, Ciani O, et al. Impact of exercise rehabilitation on exercise capacity and quality-of-life in heart failure: individual participant meta-analysis. J Am Coll Cardiol. (2019) 73:1430-43. doi: 10.1016/j.jacc.2018.12.072
5. Kumar AA, Kelly DP, Chirinos JA. Mitochondrial dysfunction in heart failure with preserved ejection fraction. Circulation. (2019) 139:1435-50. doi: 10.1161/CIRCULATIONAHA.118.036259
6. Houistsis NE, Eismann AS, Pappagianopoulos PP, Wooster L, Bailey CS, Wagner PD, et al. Exercise intolerance in heart failure with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis. Circulation. (2018) 137:148-61. doi: 10.1161/CIRCULATIONAHA.117.029058
7. Ulrich S, Hasler ED, Müller-Mottet S, Keusch S, Furian M, Latshang TD, et al. Mechanisms of improved exercise performance under hyperoxia. Respiration. (2017) 93:90-8. doi: 10.1159/000453620
8. Ulrich S, Hasler ED, Saxer S, Furian M, Muller-Mottet S, Keusch S, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with precapillary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur Heart J. (2017) 38:1159-68. doi: 10.1093/eurheartj/ehx099
9. Hasler ED, Saxer S, Schneider SR, Furian M, Lichtblau M, Schwarz El, et al. Effect of breathing oxygen-enriched air on exercise performance in patients with chronic obstructive pulmonary disease: randomized, placebo-controlled, cross-over trial. Respirat. (2020) 99:213-24. doi: 10.1159/000505819
10. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPCC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. (2016) 37:67-119. doi: 10.1093/eurheartj/ehv317
11. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. (2013) 310:2191-4. doi: 10.1001/jama.2013.281053
12. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol. (2016) 69:1167. doi: 10.1002/ehj.31592

13. Ulrich S, Schneider SR, Bloch KE. Effect of hypoxia and hyperoxia on exercise performance in healthy individuals and in patients with pulmonary hypertension: a systematic review. J Appl Physiol (1985). (2017) 123:1657-70. doi: 10.1152/japplphysiol.00186.2017

14. Subudhi AW, Dimmen AC, Roach RC. Effects of acute hypoxia on cerebral and muscle oxygenation during incremental exercise. J Appl Physiol (1985). (2007) 103:177-83. doi: 10.1152/japplphysiol.01460.2006

15. Ulrich S, Nussbaumer-Ochsner Y, Vasic I, Hasler E, Latshang TD, Kohler M, et al. Cerebral oxygenation in patients with OSA: effects of hypoxia at altitude and impact of acetazolamide. Chest. (2014) 146:299-308. doi: 10.1378/chest.13-2967

16. Muller-Mottet S, Hildenbrand FF, Keusch H, Hasler E, Maggiorini M, Speich R, et al. Effects of exercise and vasodilators on cerebral tissue oxygenation in pulmonary hypertension. Lung. (2014) 193:113-20. doi: 10.1007/s00408-014-9667-5

17. Ferreira EV, Ota-Arakaki JS, Ramos RP, Barbosa PB, Almeida M, Treptow EC, et al. Optimizing the evaluation of excess exercise ventilation for prognosis assessment in pulmonary arterial hypertension. Eur J Prev Cardiol. (2014) 21:1409-19. doi: 10.1177/2047487313494293

18. Glaser S, Ittermann T, Schaper C, Obst A, Dorr M, Spielhagen T, et al. The study of health in Pomerania (SHIP) reference values for cardiopulmonary exercise testing. Pneumologie. (2013) 67:58-63. doi: 10.1055/s-0032-1325951

19. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD. (2005) 2:131-6. doi: 10.1081/COPD-200050576

20. Puhna MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J. (2011) 37:784-90. doi: 10.1183/09031936.00063810

21. Sperlich B, Zinner C, Hauser A, Holmberg HC, Wegrzyk J. The impact of hyperoxia on human performance and recovery. Sports Med. (2017) 47:429-38. doi: 10.1007/s40279-016-0590-1

22. Noakes TD, Peltonen JE, Rusko HK. Evidence that a central governor regulates exercise performance during acute hypoxia and hyperoxia. J Exp Biol. (2001) 204:2325-34. doi: 10.1242/jeb.204.18.3225

23. Yan Z, Spaulding HR. Extracellular superoxide dismutase, a molecular transducer of health benefits of exercise. Redox Biol. (2020) 32:101508. doi:10.1016/j.redox.2020.101508

24. Aad G, Abayyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelali AA, et al. Observation of associated near-side and away-side long-range correlations in sqrt(s(NN))=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett. (2013) 110:182302. doi: 10.1103/PhysRevLett.110.182302

25. Prieur F, Benoit H, Hasler E, Latshang TD, Kohler M, et al. Reduced norepinephrine response to dynamic exercise in subjects during O2 breathing. J Appl Physiol Respir Environ Exerc Physiol. (1981) 51:176-8. doi: 10.1152/japplphysiol.1981.51.1.1176

26. Howley ET, Cox RH, Welch HG, Adams RP. Effect of hyperoxia on metabolic and catecholamine responses to prolonged exercise. J Appl Physiol Respir Environ Exerc Physiol. (1983) 54:59-63. doi: 10.1152/japplphysiol.1983.54.1.59

27. Sarmma S, Levine BD. Soothing the sleeping giant: improving skeletal muscle oxygen kinetics and exercise intolerance in HFpEF. J Appl Physiol (1985). (2015) 119:734-8. doi: 10.1152/japplphysiol.0127.2014

28. Kaykowski MJ, Brubaker PH, John JM, Stewart KP, Morgan TM, Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. J Am Coll Cardiol. (2011) 58:265-74. doi: 10.1016/j.jacc.2011.02.055

29. Dober D, van Veldhuisen DJ, Dejonge MJ, Lucas C, Cleuren G, Sanderman R, et al. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail. (2007) 9:280-6. doi: 10.1016/j.ejheart.2006.07.008

30. Bernardi L, Porta C, Spicuzza L, Bellwon J, Spadacini G, Frey AW, et al. Slow breathing increases arterial baroreflex sensitivity in patients with chronic heart failure. Circulation. (2002) 105:143-5. doi: 10.1161/01.hc0202.103311

31. Plet J, Pedersen PK, Jensen FB, Hansen JK. Increased working capacity with hyperoxia in humans. Eur J Appl Physiol Occup Physiol. (1992) 65:171-7. doi: 10.1007/BF00705076

32. Ammann M, Eldridge MW, Lovering AT, Stickland MK, Pegelow DF, Dempsey JA. Arterial oxygenation influences central motor output and exercise performance via effects on peripheral locomotor muscle fatigue. J Physiol. (2006) 575:937-52. doi: 10.1113/jphysiol.2006.113936

33. Linossier MT, Dormois D, Aras L, Denis C, Gay JP, Geyssant A, et al. Effect of hyperoxia on aerobic and anaerobic performances and muscle metabolism during maximal cycling exercise. Acta Physiol Scand. (2000) 168:403-11. doi: 10.1046/j.1365-201x.2000.00648.x

34. Oussaidene K, Prieur F, Bougault V, Borel B, Matran R, Mucci P. Cerebral oxygenation during hyperoxia-induced increase in exercise tolerance for untrained men. Eur J Appl Physiol. (2013) 113:2047-56. doi: 10.1007/s00421-013-2637-4

35. Wilkerson DP, Berger NJ, Jones AM. Influence of hyperoxia on pulmonary O2 uptake kinetics following the onset of exercise in humans. Respir Physiol Neurobiol. (2006) 153:92-106. doi: 10.1016/j.resp.2005.09.006

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Müller, Lichtblau, Saxer, Calendo, Carta, Schneider, Berlier, Furian, Bloch, Schwarz and Ulrich. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.